I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Neovascular Age Related Macular

Neovascular Age Related Macular Degeneration

nAMD is an advanced form of age-related macular degeneration, a progressive retinal disease, characterised by choroidal neovascularization (or ocular angiogenesis) and vascular leakage into the retina, resulting in rapid and severe loss of central vision. Roche is committed to the development of new treatments and treatment strategies that optimize vision outcomes to improve the lives of patients and their caregivers.

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Key Clinical Outcomes with Faricimab▼ in Treatment-naïve Patients with Neovascular Age-Related Macular Degeneration (nAMD): Results from the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies
This presentation described results From the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies. Anatomic biomarkers of disease, including CST, retinal fluid and PED demonstrated greater improvement with faricimab▼ compared with aflibercept during head-to-head dosing in TENAYA/LUCERNE. Real-world results from FARETINA and FARWIDE were consistent with clinical trial results, showing vision gains, anatomical improvement and extended durability.
Ophthalmology Neovascular Age Related Macular Degeneration APAO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Early Fluid Resolution is Associated with Short- and Long-Term Extended Durability in Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab▼: A post hoc analysis of the TENAYA/LUCERNE Trials
This presentation summarized a post hoc analysis of the impact of maintaining extended faricimab▼ treatment intervals on visual and anatomical outcomes in the TENAYA and LUCERNE trials. Results show that faricimab▼ demonstrated greater and faster resolution of fluid vs aflibercept. The results emphasize the importance of early drying as it relates to extended durability for the patient.
Ophthalmology Neovascular Age Related Macular Degeneration APAO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Response of Large or Serous Pigment Epithelial Detachment to Faricimab▼ versus Aflibercept in Patients with Neovascular Age-related Macular Degeneration: A Subgroup Analysis from TENAYA and LUCERNE
This subgroup analysis demonstrates that faricimab▼ results in greater and faster reductions Pigment Epithelial Detachment (PED) thickness compared with aflibercept in patients with nAMD from the TENAYA and LUCERNE trials.
Ophthalmology Neovascular Age Related Macular Degeneration APAO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Long-Term Efficacy and Safety of the Port Delivery Platform with Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Ladder to Portal 5-Year Subgroup Analysis
The presentation described ongoing phase 3 Portal extension trial, evaluating long-term safety and tolerability of PDS with 100 mg/mL ranibizumab in patients who completed the Ladder or Archway trials, or who will have participated in Velodrome. The PDS 100 mg/mL demonstrated stable BCVA and CPT from Ladder baseline to Portal data cut-off (60 months from implant insertion procedure). The efficacy and safety profile of PDS 100 mg/mL was maintained over 5 years of follow-up.
Ophthalmology Neovascular Age Related Macular Degeneration APAO-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 3 / Roche and Genentech
Treatment Patterns Among Medicare Advantage Plan Beneficiaries Diagnosed with Neovascular Age-Related Macular Degeneration Who Initiated Faricimab▼ Treatment
This presentation reports the real-world baseline characteristics, treatment patterns, and HCRU in patients initiating faricimab▼ for neovascular age-related macular degeneration (2022–2023). Treatment patterns and HCRU were evaluated for the 12 months before and after faricimab▼ initiation using claims analysis; results were stratified according to history of prior anti-VEGF therapy (VEGF-experienced vs VEGF-naive).
Ophthalmology Neovascular Age Related Macular Degeneration AMCP-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 16 / Roche and Genentech
Implementation of Optimized Surgical Steps for the PDS and the Incidence of Endophthalmitis and Associated Patient Outcomes
This presentation decribes results from a retrospective analysis which examined the impact of surgical improvements on endophthalmitis incidence and patient outcomes over time in patients receiving the Port Delivery Platform with ranibizumab (PDS) in the PDS clinical development program from 2016 to 2024. A trend for improvement in endophthalmitis incidence and patient outcomes was observed after June 2020. Key updates, increased awareness, better monitoring and management in the PDS clinical trial program have all contributed to this positive trend.
Ophthalmology Neovascular Age Related Macular Degeneration Diabetic Retinopathy Diabetic Macular Edema MACULA-SOCIETY-2025
Related website
Eye on Angiopoietins
Discover how angiopoietins regulate vascular stability under normal conditions and drive vascular instability in retinal and choroidal vascular diseases.
Learn more

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.